BofA Downgrades DraftKings to Neutral, Cuts Price Target to $35
BofA cuts DraftKings rating to Neutral from Buy and lowers the price target to $35 from $48, citing four key concerns about volatility, iGaming, taxes, and market sentiment.
BofA cuts DraftKings rating to Neutral from Buy and lowers the price target to $35 from $48, citing four key concerns about volatility, iGaming, taxes, and market sentiment.
Werewolf Therapeutics announces a 64% workforce reduction to save money, key executives leave with severance, and a new finance officer steps in as the company explores partnerships and funding options.
Disc Medicine's bitopertin gets turned down by FDA for treating EPP, a painful genetic condition making skin ultra-sensitive to sun.
ICE plans to spend $38.3 billion converting warehouses nationwide—including one near Hagerstown, MD—into large detention facilities for mass deportations. Companies like CoreCivic and GEO Group stand to benefit from the immigration detention boom.